Retatrutide is an investigational peptide being studied in people with obesity, overweight, and type 2 diabetes. It has attracted attention because one molecule engages three hormone receptors. But the most useful question is not how many receptors it reaches. It is what controlled studies have actually measured, in whom, and for how long.
What is retatrutide?
Retatrutide, also called LY3437943 in trial records, is a single molecule designed to activate receptors for three hormones: GIP, GLP-1, and glucagon. These signals are involved in how the body handles food and energy. Scientists sometimes call retatrutide a “triple agonist.” In plain English, that means it can switch on three different hormone receptors. It does not mean that each receptor contributes an equal or separately proven share of a clinical result. The effect that matters to readers is the outcome measured in a human study, not the receptor count alone. The published Phase 2 obesity trial describes both the molecule and the outcomes its investigators measured.
What did the published obesity study find?
The 2023 randomized, double-blind Phase 2 trial enrolled 338 adults with obesity, or overweight plus a weight-related condition. Participants were assigned to retatrutide or placebo for 48 weeks. The planned primary measurement was percentage change in body weight after 24 weeks; the 48-week change was a secondary outcome.
At 24 weeks, the reported mean weight change in the 12 mg study group was −17.5%, compared with −1.6% for placebo. At 48 weeks, those figures were −24.2% and −2.1%. These are group averages in a specific trial, not a prediction for an individual. The study also reported different results across the other assigned groups. Its design lets us compare the studied groups, but a 48-week trial cannot answer every question about longer-term outcomes. Read the original trial abstract and methods.
What about blood sugar research?
A separate 2023 Phase 2 trial studied 281 adults with type 2 diabetes. Investigators compared retatrutide with placebo and an active comparator, then measured changes in HbA1c, a marker of average blood sugar over roughly three months, as well as body weight. The trial reported reductions in both measures in its studied groups. It had a different population, comparator structure, and follow-up period from the obesity trial, so the two studies should not be blended into one headline number. The published diabetes trial is the source for its own endpoints and safety findings.
What is new in phase 3?
The 2026 TRIUMPH-1 publication reports an 80-week randomized placebo-controlled study in adults with obesity without diabetes. The TRIUMPH-2 publication separately evaluates adults with obesity and type 2 diabetes. These published records now provide a stronger basis for examining methods than sponsor headlines alone. They should be read separately because the populations and endpoint analyses differ. The older phase 2 studies below remain historical evidence, not a description of the entire current programme.
Compare intention-to-treat and adherence-related analyses carefully, and retain the study population alongside every numerical result. A phase 3 publication does not by itself establish regulatory approval, product equivalence or a personal treatment recommendation. This update identifies new primary reports without presenting a cross-trial efficacy ranking.
What did the studies report about safety?
The published Phase 2 obesity trial reported that gastrointestinal events were the most common adverse events in retatrutide groups. They were generally mild to moderate, varied with assigned group, and occurred more often than with placebo. Investigators also observed increases in heart rate that peaked around week 24 and then declined. The paper reports these alongside the weight findings; leaving them out would give an incomplete picture. The Phase 3 top-line report described nausea, diarrhea, constipation, and vomiting among frequently observed events. Full reports and longer follow-up are needed to understand the complete benefit-and-risk picture.
How should a reader interpret the evidence?
- Start with the source type. A peer-reviewed randomized trial contains more detail than a top-line announcement.
- Keep the population attached. Results from adults with obesity without diabetes are not interchangeable with results from adults with type 2 diabetes or cardiovascular disease.
- Check the time point and analysis. A 24-week primary endpoint, a 48-week secondary endpoint, and an 80-week Phase 3 estimate answer different questions.
- Read benefits and adverse events together. A large average change does not erase variability, discontinuations, or unanswered long-term questions.
For more context on why a primary endpoint matters, see our guide to clinical trial endpoints. The clearest summary of retatrutide research is therefore specific: it is a three-receptor investigational peptide with encouraging controlled human data, while each reported outcome has a defined population, time point, and evidence level.
